Background: Vitiligo is an acquired autoimmune disorder characterized by patchy depigmentation in the skin and hair. Dysregulation of lipid metabolism and immune dysregulation are key factors in the pathogenesis of vitiligo. Apolipoprotein E4 (ApoE4), a protein involved in lipid metabolism, has been implicated in various health conditions. Assessing serum levels of ApoE4 in patients with vitiligo may provide insights into the disease process and clinical implications. 1.Introduction Vitiligo is an acquired, idiopathic, auto-immune condition characterised by patchy depigmentation of the skin, hair, or both. This illness affects a considerable fraction of the worldwide population, with an estimated frequency among adults and children of 0.5-2 %. Vitiligo is characterised by the emergence of amelanotic, milky white macules or patches with well-defined boundaries, surrounded by unaffected skin Objective: The review aims to explore the potential role of ApoE4 in vitiligo pathogenesis, its association with lipid metabolism and immune dysregulation, and the clinical implications of altered ApoE4 levels. Conclusions: In conclusion, the assessment of serum levels of Apolipoprotein E4 (ApoE4) in patients with vitiligo holds promise as a potential avenue for understanding the disease and its clinical implications.